{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:06Z","timestamp":1791357366896,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1124\/dmd.107.015354","type":"journal-article","created":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:50:06Z","timestamp":1177980606000},"page":"1292-1300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17"],"prefix":"10.1016","volume":"35","author":[{"given":"Hongwu","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxia M.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houfu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Wrighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.107.015354_bib1","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0006-2952(02)01351-5","article-title":"The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant: potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations","volume":"64","author":"Bapiro","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib2","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tiv.2005.04.001","article-title":"Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles","volume":"19","author":"Bogni","year":"2005","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/dmd.107.015354_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.tpj.6500378","article-title":"CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing","volume":"6","author":"Cai","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.107.015354_bib4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00008571-199808000-00006","article-title":"Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians","volume":"8","author":"Droll","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.107.015354_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/bj2810359","article-title":"Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics","volume":"281","author":"Forrester","year":"1992","journal-title":"Biochem J"},{"key":"10.1124\/dmd.107.015354_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/abbi.2000.1936","article-title":"The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6","volume":"380","author":"Fukuda","year":"2000","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.107.015354_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1067\/mcp.2002.125783","article-title":"Unique CYP2D6 activity distribution and genotype-phenotype discordance in blank Americans","volume":"72","author":"Gaedigk","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.015354_bib8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","article-title":"Pharmacogenetics, drug-metabolizing enzymes, and clinical practice","volume":"58","author":"Gardiner","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.107.015354_bib9","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJM199411173312008","article-title":"Fluoxetine","volume":"331","author":"Gram","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.107.015354_bib10","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bcp.2006.01.019","article-title":"Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae.","volume":"71","author":"Hanioka","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/clpt.1989.126","article-title":"Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese","volume":"46","author":"Horai","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.015354_bib12","first-page":"1780","article-title":"Genetic polymorphisms of CYP2D6 in Chinese mainland","volume":"115","author":"Ji","year":"2002","journal-title":"Chin Med J"},{"key":"10.1124\/dmd.107.015354_bib13","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1139\/y80-173","article-title":"Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals","volume":"58","author":"Kalow","year":"1980","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib14","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1124\/dmd.30.5.595","article-title":"Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine","volume":"30","author":"Marcucci","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0026-895X(24)12048-2","article-title":"(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes","volume":"28","author":"Margolis","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2125.1996.00489.x","article-title":"A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity","volume":"42","author":"Masimirembwa","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/clpt.1990.4","article-title":"Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P-450IID1","volume":"47","author":"Mortimer","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.015354_bib18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0006-291X(02)00328-5","article-title":"CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability","volume":"293","author":"Nakamura","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.107.015354_bib19","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004583-200503000-00008","article-title":"Atomoxetine treatment in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"44","author":"Newcorn","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1124\/dmd.107.015354_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molbrainres.2004.06.030","article-title":"Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6","volume":"129","author":"Niwa","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1124\/dmd.107.015354_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1124\/mol.52.6.1034","article-title":"A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function","volume":"52","author":"Oscarson","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00008571-200108000-00003","article-title":"Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates","volume":"11","author":"Ramamoorthy","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.107.015354_bib23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/S0006-2952(02)01028-6","article-title":"Reduced (\u00b1)-3,4-methylenedioxymethamphetamine (\u201cEcstasy\u201d) metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro","volume":"63","author":"Ramamoorthy","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0022-3565(24)29631-2","article-title":"Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine","volume":"297","author":"Ring","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.015354_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/dmd.30.3.319","article-title":"Identification of the human cytochromes P450 responsible for atomoxetine metabolism","volume":"30","author":"Ring","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib26","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1124\/dmd.107.015354_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/dmd.31.1.98","article-title":"Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism","volume":"31","author":"Sauer","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I: analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.107.015354_bib29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1124\/dmd.30.10.1102","article-title":"Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin","volume":"30","author":"Shin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib30","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0090-9556(24)15029-5","article-title":"Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6","volume":"27","author":"Shin","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0022-3565(25)38409-0","article-title":"Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450","volume":"266","author":"Stevens","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.015354_bib32","first-page":"1146","article-title":"Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes","volume":"29","author":"Subrahmanyam","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.107.015354_bib33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0009-9236(99)70077-9","article-title":"Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population","volume":"65","author":"Tateishi","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.107.015354_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0026-895X(25)12855-1","article-title":"Neuronal cytochrome P450IID1 (debrisoquine\/sparteine-type): potent inhibition of activity by (\u2013)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6","volume":"40","author":"Tyndale","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/00912709922008173","article-title":"Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs","volume":"39","author":"Venkatakrishnan","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.107.015354_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/prep.2001.1578","article-title":"Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.","volume":"24","author":"Yamazaki","year":"2002","journal-title":"Protein Expr Purif"},{"key":"10.1124\/dmd.107.015354_bib37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1124\/jpet.102.039891","article-title":"Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms","volume":"303","author":"Yu","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.107.015354_bib38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008571-200110000-00004","article-title":"Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6","volume":"11","author":"Zanger","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.107.015354_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","article-title":"Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry","volume":"369","author":"Zanger","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624013758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.107.015354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:20:43Z","timestamp":1739895643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624013758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0090955624013758"],"URL":"https:\/\/doi.org\/10.1124\/dmd.107.015354","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.107.015354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2007 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}